Publication:
PD-L1ATTAC mice reveal the potential of depleting PD-L1 expressing cells in cancer therapy.

dc.contributor.authorFueyo-Marcos, Elena
dc.contributor.authorLopez-Pernas, Gema
dc.contributor.authorFustero-Torre, Coral
dc.contributor.authorAntón, Marta Elena
dc.contributor.authorAl-Shahrour, Fatima
dc.contributor.authorFernández-Capetillo, Oscar
dc.contributor.authorMurga, Matilde
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderAsociación Española Contra el Cáncer
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)
dc.date.accessioned2024-02-09T12:00:16Z
dc.date.available2024-02-09T12:00:16Z
dc.date.issued2023-03-22
dc.description.abstractAntibodies targeting the PD-1 receptor and its ligand PD-L1 have shown impressive responses in some tumors of bad prognosis. We hypothesized that, since immunosuppressive cells might present several immune checkpoints on their surface, the selective elimination of PD-L1 expressing cells could be efficacious in enabling the activation of antitumoral immune responses. To address this question, we developed an inducible suicidal knock-in mouse allele of Pd-l1 (PD-L1ATTAC) which allows for the tracking and specific elimination of PD-L1-expressing cells in adult tissues. Consistent with our hypothesis, elimination of PD-L1 expressing cells from the mouse peritoneum increased the septic response to lipopolysaccharide (LPS), due to an exacerbated inflammatory response to the endotoxin. In addition, mice depleted of PD-L1+ cells were resistant to colon cancer peritoneal allografts, which was associated with a loss of immunosuppressive B cells and macrophages, concomitant with an increase in activated cytotoxic CD8 T cells. Collectively, these results illustrate the usefulness of PD-L1ATTAC mice for research in immunotherapy and provide genetic support to the concept of targeting PD-L1 expressing cells in cancer.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipO.F-C. is supported by grants from the Spanish Ministry of Science, Innovation and Universities (PID2021- 128722OB-I00, co-financed with European FEDER funds) and the Spanish Association Against Cancer (AECC; PROYE20101FERN) to O.F-C. and by a Ph.D. fellowship from Mar?a Oliva-Amigos/as del CNIO to E.F-M. The CNIO Bioinformatics Unit (BU) is a member of the Spanish National Bioinformatics Institute (INB) , ISCIII- Bioinformatics platform and is supported by grant PT17/0009/0011, of the Accion Estrategica en Salud 2013-2016 of the Programa Estatal de Investigacion Orientada a los Retos de la Sociedad, funded by the ISCIII and European Regional Development Fund (ERDF-EU) and project RETOS RTI2018-097596-B-I00 funded by AEI-MCIU and cofounded by the ERDF-EU. The authors declare no competing financial interests.es_ES
dc.format.number6es_ES
dc.format.page1791es_ES
dc.format.volume15es_ES
dc.identifier.citationAging (Albany NY) . 2023;15(6):1791-1807.es_ES
dc.identifier.doi10.18632/aging.204598es_ES
dc.identifier.e-issn1945-4589es_ES
dc.identifier.journalAginges_ES
dc.identifier.pubmedID36947705es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17696
dc.language.isoenges_ES
dc.publisherImpact Journals
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PID2021- 128722OB-I00es_ES
dc.relation.publisherversionhttps://doi.org/10.18632/aging.204598.es_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Inestabilidad Genómicaes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshAntineoplastic Agentses_ES
dc.subject.meshNeoplasmses_ES
dc.subject.meshMicees_ES
dc.subject.meshAnimalses_ES
dc.subject.meshB7-H1 Antigenes_ES
dc.subject.meshImmunotherapyes_ES
dc.subject.meshT-Lymphocytes, Cytotoxices_ES
dc.subject.meshCell Line, Tumores_ES
dc.subject.meshCD8-Positive T-Lymphocyteses_ES
dc.subject.meshTumor Microenvironmentes_ES
dc.titlePD-L1ATTAC mice reveal the potential of depleting PD-L1 expressing cells in cancer therapy.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionNAes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication109ab297-8df3-458e-9a03-0dd210ea8e09
relation.isAuthorOfPublication.latestForDiscovery109ab297-8df3-458e-9a03-0dd210ea8e09
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication453a1189-9bca-4be8-8d60-695f50fe028b
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication1aef4c3b-1ee5-4534-83b4-3f3811c67280
relation.isFunderOfPublication.latestForDiscoveryefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isPublisherOfPublication308f485e-2d81-409c-85ad-82f4b1afd9a1
relation.isPublisherOfPublication.latestForDiscovery308f485e-2d81-409c-85ad-82f4b1afd9a1

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PD-L1ATTAC mice reveal_2023.docx
Size:
3.1 MB
Format:
Microsoft Word XML
Description:
Artículo principal